Xencor Inc (XNCR)
Debt-to-capital ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 677,611 | 668,796 | 727,496 | 733,504 | 572,444 |
Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $677,611K)
= 0.00
The debt-to-capital ratio of Xencor Inc has consistently remained at 0.00 from December 31, 2020, through December 31, 2024. This indicates that the company has not utilized any debt in its capital structure during this period. A debt-to-capital ratio of 0.00 suggests that the company's capital is entirely derived from equity rather than debt financing. This can be viewed positively by investors and creditors as it signifies a lower financial risk and a more conservative financial profile for Xencor Inc.
Peer comparison
Dec 31, 2024
Company name
Symbol
Debt-to-capital ratio
Xencor Inc
XNCR
0.00
Abbott Laboratories
ABT
0.00
AbbVie Inc
ABBV
0.00
ACADIA Pharmaceuticals Inc
ACAD
0.00
Alkermes Plc
ALKS
0.00
Amphastar P
AMPH
0.46
ANI Pharmaceuticals Inc
ANIP
0.00
Arcus Biosciences Inc
RCUS
0.00
Biomarin Pharmaceutical Inc
BMRN
0.10
Bristol-Myers Squibb Company
BMY
0.74
Catalyst Pharmaceuticals Inc
CPRX
0.00